Treatment of Oromandibular Dystonia, Bruxism, and Temporomandibular Disorders with Botulinum Toxin

2009 ◽  
pp. 204-213
Author(s):  
Nwanmegha Young ◽  
Andrew Blitzer
Keyword(s):  
Botulinum Toxin ◽  
Temporomandibular Disorders ◽  
Oromandibular Dystonia

scholarly journals Effects of Botulinum Toxin Type A on Pain among Trigeminal Neuralgia, Myofascial Temporomandibular Disorders, and Oromandibular Dystonia

Toxins ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 605
Author(s):  
Kazuya Yoshida
Keyword(s):  
Botulinum Toxin ◽  
Trigeminal Neuralgia ◽  
Temporomandibular Disorders ◽  
Myofascial Pain ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Oromandibular Dystonia ◽  
Botulinum Toxin Therapy ◽  
Pain Frequency

The differences in analgesic effects of botulinum toxin type A were compared in 28 patients with trigeminal neuralgia, 53 patients with myofascial temporomandibular disorders, and 89 patients with the jaw closing oromandibular dystonia. The patients were treated by injection of botulinum toxin type A into the masseter, temporalis, medial pterygoid, and other muscles based on the symptoms of each patient. The pain severity was evaluated using the visual analog scale, pain frequency, and pain scale of the oromandibular dystonia rating scale. Botulinum toxin injection was performed 1068 times in all patients without significant adverse effects. The visual analog, pain frequency, and pain scales at baseline were reduced (p < 0.001) after two, four, eight, and 12 weeks after the first botulinum toxin therapy and at the endpoint. The effects differed significantly (p < 0.001) among the groups (repeated-measures analysis of variance). The mean improvement (0%, no effect; 100%, complete recovery) at the endpoint was 86.8% for trigeminal neuralgia, 80.8% for myofascial pain, and 75.4% for oromandibular dystonia. Injection of the botulinum toxin can be a highly effective and safe method to treat trigeminal neuralgia, myofascial pain, and oromandibular dystonia.

scholarly journals Assessing the effectiveness of botulinum toxin injections into masticatory muscles in the treatment of temporomandibular disorders

2018 ◽  
Vol 24 (3) ◽  
pp. 107-111 ◽  
Author(s):  
Alexis Kahn ◽  
Helios Bertin ◽  
Pierre Corre ◽  
Morgan Praud ◽  
Arnaud Paré ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Temporomandibular Disorders ◽  
Myofascial Pain ◽  
Mouth Opening ◽  
Masticatory Muscles ◽  
University Hospital ◽  
Duration Of Action ◽  
Beneficial Effects ◽  
Duration Of Effect ◽  
The Mean

Introduction: Temporomandibular disorders (TMD) are a common and invalidating disease sometimes difficult to treat. Current international recommendations favour reversible and non-invasive treatments, including the injection of botulinum toxin (BTX) into masticatory muscles. There is no strong evidence of its effectiveness. Objective: The main goal of this study was to assess the effectiveness of BTX six months following injection, in terms of pain, mouth opening, improvement of symptoms and duration of effect. Materials and methods: A retrospective study carried out at Nantes University Hospital between 2014 and 2016. Results: Thirty-four patients were included. The mean age was 37 years (17–76) and seventy six percents were female. Eighty percent of patients reported a significant improvement, notably in cases of arthralgia, which decreased in 8/18 (44%) patients (p < 0.05). The mean duration of measured efficacy was 4.2 months. Discussion: Significant improvement in cases of arthralgia and a tendency for improvement in cases of myalgia, with a mean duration of action of 4.2 months. Although BTX injection do not guarantee complete resolution of myofascial pain, it have been shown to have beneficial effects on some symptoms have been shown. Conclusion: Botulinum toxin should be considered as an alternative treatment when other conservative methods fail to yield satisfactory results. A thorough multicentre assessment is necessary in the future to scientifically validate its use.

Oromandibular dystonia: Long-term management with botulinum toxin

2013 ◽  
Vol 123 (12) ◽  
pp. 3078-3083 ◽  
Author(s):  
Catherine F. Sinclair ◽  
Lowell E. Gurey ◽  
Andrew Blitzer
Keyword(s):  
Botulinum Toxin ◽  
Oromandibular Dystonia ◽  
Term Management

Treatment of Temporomandibular Disorders with Botulinum Toxin

2002 ◽  
Vol 18 (Supplement) ◽  
pp. S198-S203 ◽  
Author(s):  
Marvin Schwartz ◽  
Brian Freund
Keyword(s):  
Botulinum Toxin ◽  
Temporomandibular Disorders

A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism

BDJ ◽  
2019 ◽  
Vol 226 (9) ◽  
pp. 667-672 ◽  
Author(s):  
Jalpesh Patel ◽  
Jorge A. Cardoso ◽  
Shamir Mehta
Keyword(s):  
Systematic Review ◽  
Botulinum Toxin ◽  
Temporomandibular Disorders

scholarly journals 1218 Obstructive Sleep Apnea Due To Oromandibular Dystonia And Treated With Botulinum Toxin

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A465-A466
Author(s):  
Caleb Hsieh ◽  
Nancy Hsu ◽  
Aaron Thomas ◽  
Melisa Chang ◽  
Armand Ryden ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Botulinum Toxin ◽  
Sleep Apnea ◽  
Upper Airway ◽  
Oromandibular Dystonia ◽  
Persistent Symptoms ◽  
Obstructive Sleep ◽  
Respiratory Event ◽  
Botulinum Toxin Injections ◽  
Masseter Muscles

Abstract Introduction Abnormalities of the upper airway are an underrecognized cause of obstructive sleep apnea (OSA). Oromandibular dystonia (OMD) is characterized by involuntary contractions of the masticatory, facial, pharyngeal or laryngeal muscles usually resulting in pain, dysarthria, dysphagia, or impaired mastication. We present a patient with OMD manifest as episodic OSA and sleep maintenance insomnia treated effectively with botulinum toxin injections of the temporalis and masseter muscles. Report of Case A 51-year-old man was referred for fatigue and insomnia. History was notable for prior facial trauma requiring jaw surgeries with titanium prostheses and chronic OMD requiring periodic botulinum toxin injections of the temporalis and masseter muscles. An initial home sleep test (HST) 43 days after the last botulinum toxin injection showed a respiratory event index of 6.5 events/hour. Given severity of symptoms, positive airway pressure (PAP) was initiated; however, due to poor tolerance and persistent symptoms, he was referred for attended polysomnography (PSG). The PSG was done 13 days after an injection and showed apnea-hypopnea index (AHI) of 0 events/hour. Because the patient continued to endorse episodically severe symptoms that he felt paralleled the severity of OMD and waning of botulinum toxin effect, a repeat PSG was performed at a subjective botulinum toxin effect nadir. This PSG done at 83 days post-injection demonstrated AHI of 84 events/hour. PAP therapy was thus resumed, and the patient’s symptoms improved with increased frequency of botulinum toxin treatments. Conclusion To our knowledge, this is the first report of OSA due to chronic dystonia of the facial muscles. Botulinum toxin has demonstrated benefit in the treatment of OMD with efficacy generally lasting three to six months. While PAP remains the first-line treatment for OSA, in patients with structural or functional abnormalities of the upper airway, it is important to also consider treatment of the underlying anatomical defect.

Sign in / Sign up

Export Citation Format

Share Document